JP2000500019A5 - - Google Patents

Download PDF

Info

Publication number
JP2000500019A5
JP2000500019A5 JP1997518551A JP51855197A JP2000500019A5 JP 2000500019 A5 JP2000500019 A5 JP 2000500019A5 JP 1997518551 A JP1997518551 A JP 1997518551A JP 51855197 A JP51855197 A JP 51855197A JP 2000500019 A5 JP2000500019 A5 JP 2000500019A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997518551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000500019A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1996/004850 external-priority patent/WO1997018314A1/de
Publication of JP2000500019A publication Critical patent/JP2000500019A/ja
Publication of JP2000500019A5 publication Critical patent/JP2000500019A5/ja
Ceased legal-status Critical Current

Links

JP9518551A 1995-11-16 1996-11-06 ストレプトアビジン融合タンパク質経由でのペプチドの生産方法 Ceased JP2000500019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19542702 1995-11-16
DE19542702.5 1995-11-16
PCT/EP1996/004850 WO1997018314A1 (de) 1995-11-16 1996-11-06 Verfahren zur herstellung von peptiden über streptavidin-fusionsproteine

Publications (2)

Publication Number Publication Date
JP2000500019A JP2000500019A (ja) 2000-01-11
JP2000500019A5 true JP2000500019A5 (enExample) 2004-11-04

Family

ID=7777604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9518551A Ceased JP2000500019A (ja) 1995-11-16 1996-11-06 ストレプトアビジン融合タンパク質経由でのペプチドの生産方法

Country Status (6)

Country Link
US (1) US6136564A (enExample)
EP (1) EP0861325A1 (enExample)
JP (1) JP2000500019A (enExample)
AU (1) AU7566396A (enExample)
CA (1) CA2237296C (enExample)
WO (1) WO1997018314A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168718A1 (en) * 1997-04-03 2002-11-14 California Institute Of Technology Enzyme-mediated modification of fibrin for tissue engineering
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP2311895B1 (en) 1999-02-01 2017-04-12 Eidgenössische Technische Hochschule Zürich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
EP1190061A1 (en) * 1999-06-07 2002-03-27 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7291673B2 (en) * 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP1465989B1 (en) * 2001-12-18 2008-02-20 Eidgenossisch Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
CA2470419A1 (en) * 2001-12-18 2003-06-26 Eidgenossisch Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
AU2005318097A1 (en) * 2004-12-22 2006-06-29 Kuros Biosurgery Ag Michael-type addition reaction functionalised peg hydrogels with factor XIIIA incorporated biofactors
WO2006072622A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
WO2008125655A1 (en) * 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
EP2227263A2 (en) * 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
CN102712696A (zh) * 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Fc-영역 접합체의 제조 방법 및 그의 용도
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2624470B2 (ja) * 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド ストレプトアビジン様ポリペプチドの製造
GB8518753D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Microbiological products
DE3878231T2 (de) * 1987-03-02 1993-05-27 Bissendorf Peptide Gmbh Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
GB8723661D0 (en) * 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
ATE253639T1 (de) * 1991-08-19 2003-11-15 Daiichi Suntory Pharma Co Ltd Verfahren zur herstellung von peptiden

Similar Documents

Publication Publication Date Title
JP2000500228A5 (enExample)
JP2000500445A5 (enExample)
JP2000500440A5 (enExample)
JP2000500327A5 (enExample)
JP2000500155A5 (enExample)
JPH11507533A5 (enExample)
JP2000500361A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JPH11506886A5 (enExample)
JP2000500166A5 (enExample)
JP2000500051A5 (enExample)
JP2000500407A5 (enExample)
JP2000500397A5 (enExample)
JP2000500125A5 (enExample)
JP2000500346A5 (enExample)
JPH10510459A5 (enExample)
JP2000500044A5 (enExample)
JP2000500090A5 (enExample)
JP2000500429A5 (enExample)
JP2000500106A5 (enExample)
JPH11513276A5 (enExample)